Case Based Review

Clinical Rheumatology

, Volume 32, Issue 2, pp 281-283

Rituximab-induced regression of CREST-related calcinosis

  • Dayane Raquel de PaulaAffiliated withFaculty of Medicine, Federal University of Paraná
  • , Fabiane Barbero KlemAffiliated withFaculty of Medicine, Federal University of Paraná
  • , Pedro Gabriel LorencettiAffiliated withFaculty of Medicine, Federal University of Paraná
  • , Carolina MullerAffiliated withScleroderma Outpatient Clinic, Hospital de Clinicas, Federal University of Paraná
  • , Valderilio Feijó AzevedoAffiliated withHospital de Clinicas, Federal University of ParanáEdumed-Health Research and Education Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m2 each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma.


Calcinosis Rituximab Scleroderma Treatment